INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46301, 'Bosentan', 'Pegaspargase', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46371/', '', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46302, 'Bosentan', 'Peginterferon beta-1a', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46372/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46303, 'Bosentan', 'Pemigatinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.', 'DDInter', 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46373/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46304, 'Bosentan', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', 'DDInter', 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46374/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More', 'Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46305, 'Bosentan', 'Perampanel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme. The interaction has been reported with known CYP450 3A4 inducers such as carbamazepine, oxcarbazepine, and phenytoin.', 'DDInter', 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46375/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Mephenytoin, Fenfluramine, Lamotrigine, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46306, 'Bosentan', 'Pexidartinib', 'Major', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.', 'DDInter', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46376/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Tioconazole, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46307, 'Bosentan', 'Phenylbutazone', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of bosentan, which is metabolized by these isoenzymes. Concomitant administration of both a CYP450 2C9 inhibitor and a CYP450 3A4 inhibitor may lead to even larger increases in plasma concentrations of bosentan.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with dual inhibitors of CYP450 2C9 and 3A4 (e.g., delavirdine, imatinib, miconazole, voriconazole) should probably be avoided also, if possible.', 'Metabolism', 'The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46377/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Fenoprofen, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Esomeprazole, Tolmetin, Meclofenamic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46308, 'Bosentan', 'Phenytoin', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46378/', '', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Mephenytoin, Fenfluramine, Lamotrigine, Eslicarbazepine, Phensuximide, More', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46309, 'Bosentan', 'Pimavanserin', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46379/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46310, 'Bosentan', 'Pimozide', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46380/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More', 'Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46311, 'Bosentan', 'Piroxicam', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46381/', '', 'Fenoprofen, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Esomeprazole, Tolmetin, Meclofenamic acid, More', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46312, 'Bosentan', 'Ponatinib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.', 'DDInter', 'Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided unless the benefit outweighs the potential risk of ponatinib underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ponatinib is unknown.', 'Metabolism', 'Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46382/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46313, 'Bosentan', 'Posaconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of bosentan, which is metabolized by these isoenzymes. Concomitant administration of both a CYP450 2C9 inhibitor and a CYP450 3A4 inhibitor may lead to even larger increases in plasma concentrations of bosentan.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with dual inhibitors of CYP450 2C9 and 3A4 (e.g., delavirdine, imatinib, miconazole, voriconazole) should probably be avoided also, if possible.', 'Metabolism', 'The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46383/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Darunavir, More', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46314, 'Bosentan', 'Pralsetinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A may decrease the plasma concentrations of pralsetinib which is primarily metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46384/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46315, 'Bosentan', 'Praziquantel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved. Alternative agents for schistosomiasis should be considered whenever possible in patients receiving treatment with a CYP450 3A4 inducer. Otherwise, clinical response to praziquantel should be closely monitored.', 'Metabolism', 'Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46385/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Triclabendazole, Oxamniquine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46316, 'Bosentan', 'Prednisolone', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46386/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Tioconazole, Furazolidone, Diiodohydroxyquinoline, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46317, 'Bosentan', 'Prednisone', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46387/', '', 'Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Sulfamethizole, Simeprevir, Vemurafenib, Econazole, Chloramphenicol, Povidone-iodine, More', 'Cromoglicic acid, Olsalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46318, 'Bosentan', 'Pretomanid', 'Major', 'Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme.', 'DDInter', 'The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46388/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46319, 'Bosentan', 'Progesterone', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46389/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46320, 'Bosentan', 'Progesterone (topical)', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46390/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46321, 'Bosentan', 'Quazepam', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46391/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, More', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46322, 'Bosentan', 'Quetiapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be advised to notify their physician if their symptoms worsen or their condition changes.', 'Metabolism', 'Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46392/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More', 'Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46323, 'Bosentan', 'Quinestrol', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46393/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46324, 'Bosentan', 'Quinidine', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46394/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Amphotericin B, Trichlormethiazide, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, More', 'Propafenone, Tocainide, Procainamide, Flecainide, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46325, 'Bosentan', 'Quinine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St. John''s wort. The possibility of diminished therapeutic efficacy should be considered.', 'Metabolism', 'Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46395/', '', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46326, 'Bosentan', 'Ramelteon', 'Moderate', 'Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.', 'DDInter', 'The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John''s wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.', 'Metabolism', 'The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46396/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46327, 'Bosentan', 'Ranolazine', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. The extent to which other, less potent CYP450 3A4 inducers may interact with ranolazine is unknown. Caution is advised if they are used with ranolazine.', 'Metabolism', 'The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46397/', '', 'Adenosine, Regadenoson, Alprostadil, Ubidecarenone', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46328, 'Bosentan', 'Relugolix', 'Moderate', 'Coadministration with dual inducers of CYP450 3A4 and P-glycoprotein (P-gp) may decrease the plasma concentrations of relugolix. In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8. Relugolix is also a substrate for intestinal P-gp.', 'DDInter', 'The potential for diminished pharmacologic effects of relugolix should be considered during coadministration with dual CYP450 3A4 and P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of relugolix should be considered during coadministration with dual CYP450 3A4 and P-gp inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46398/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More', 'Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46329, 'Bosentan', 'Remdesivir', 'Moderate', 'Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.', 'DDInter', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.', 'Synergism', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46399/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More', 'Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46330, 'Bosentan', 'Repaglinide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of repaglinide, which is metabolized by the isoenzyme in the intestine and liver.', 'DDInter', 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide. Blood glucose should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy in patients stabilized on their existing antidiabetic regimen, and the repaglinide dosage adjusted as necessary. Patients should be advised to contact their physician if they experience loss of glycemic control.', 'Metabolism', 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46400/', '', 'Tinidazole, Ascorbic acid, Oxytetracycline, Amphotericin B, Sumatriptan, Zonisamide, Tioconazole, Econazole, Mafenide, Brinzolamide, Furazolidone, More', 'Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Semaglutide, Dulaglutide, Exenatide, Miglitol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46331, 'Bosentan', 'Ribociclib', 'Moderate', 'Coadministration of bosentan with a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 may result in increased plasma concentrations of bosentan and decreased plasma concentrations of the other drug. Bosentan itself is a substrate and inducer of both CYP450 2C9 and 3A4. Theoretically, bosentan may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.', 'DDInter', 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered. Clinical and/or laboratory monitoring may be appropriate whenever bosentan is added to or withdrawn from therapy, and the dosage of the concomitant drug adjusted as necessary. The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with combination CYP450 2C9/3A4 inhibitors (e.g., delavirdine, imatinib, miconazole, mifepristone, voriconazole) should probably be avoided also, if possible.', 'Metabolism', 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46401/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46332, 'Bosentan', 'Rifabutin', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46402/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46333, 'Bosentan', 'Rifapentine', 'Moderate', 'Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.', 'DDInter', 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.', 'Metabolism', 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46403/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46334, 'Bosentan', 'Rilpivirine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46404/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46335, 'Bosentan', 'Rimegepant', 'Major', 'Coadministration with strong or moderate inducers of CYP450 3A4 may significantly reduce the plasma concentrations and therapeutic effects of rimegepant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46405/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46336, 'Bosentan', 'Riociguat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of riociguat, which is partially metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of riociguat adjusted as necessary. Data are not available to guide dosing of riociguat when coadministered with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort. Alternative agents with no or minimal CYP450 3A4-inducing activity should be considered whenever possible.', 'Metabolism', 'The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46406/', '', 'Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 'Bosentan, Metyrosine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46337, 'Bosentan', 'Ripretinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.', 'DDInter', 'Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.', 'Metabolism', 'Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46407/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46338, 'Bosentan', 'Ritonavir', 'Major', 'Coadministration with the pharmacokinetic boosters cobicistat and ritonavir may significantly increase the plasma concentrations of bosentan, particularly during the first few days of combined use. The proposed mechanism is inhibition of the OATP-mediated uptake of bosentan into hepatocytes.', 'DDInter', 'The dosage of bosentan should be adjusted when used in combination with cobicistat or ritonavir. In patients who have been receiving cobicistat or ritonavir for at least 10 days when bosentan is prescribed, the latter should be initiated at 62.5 mg once daily or every other day depending on individual tolerability. Conversely, in patients who have been receiving bosentan when cobicistat or ritonavir is prescribed, the manufacturers recommend that use of bosentan be discontinued for at least 36 hours prior to initiating the pharmacokinetic booster. After at least 10 days following the initiation of cobicistat or ritonavir, bosentan may be resumed at 62.5 mg once daily or every other day based upon individual tolerability. There is limited experience with abrupt discontinuation of bosentan. Although no evidence for acute rebound has been observed, gradual dose reduction (62.5 mg twice daily for 3 to 7 days) should be considered to minimize the potential for clinical deterioration.', 'Others', 'The dosage of bosentan should be adjusted when used in combination with cobicistat or ritonavir.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46408/', '', 'Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Darunavir, Tioconazole, Brinzolamide, Indapamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46339, 'Bosentan', 'Rivaroxaban', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme as well as the efflux transporter.', 'DDInter', 'Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein. Pharmacologic effects of rivaroxaban should be monitored more closely whenever the inducer is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46409/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Betrixaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46340, 'Bosentan', 'Rolapitant', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of rolapitant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46410/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More', 'Scopolamine, Nabilone, Dolasetron, Palonosetron', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46341, 'Bosentan', 'Rucaparib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of bosentan, which is metabolized by these isoenzymes. Concomitant administration of both a CYP450 2C9 inhibitor and a CYP450 3A4 inhibitor may lead to even larger increases in plasma concentrations of bosentan.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with dual inhibitors of CYP450 2C9 and 3A4 (e.g., delavirdine, imatinib, miconazole, voriconazole) should probably be avoided also, if possible.', 'Metabolism', 'The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46411/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46342, 'Bosentan', 'Rufinamide', 'Moderate', 'Rufinamide may modestly or moderately decrease the plasma concentrations and therapeutic effects of drugs that are CYP450 3A4 substrates. The mechanism is enhanced metabolism by CYP450 3A4 enzyme induction.', 'DDInter', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose. Dose adjustments of the coadministered drug may be required if an interaction is suspected.', 'Metabolism', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46412/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Mephenytoin, Fenfluramine, Lamotrigine, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46343, 'Bosentan', 'Ruxolitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer. However, patients should be closely monitored and the dose titrated based on safety and efficacy.', 'Metabolism', 'No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46413/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46344, 'Bosentan', 'Sacituzumab govitecan', 'Major', 'Coadministration with inducers of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) may significantly decrease the plasma concentrations of sacituzumab govitecan and its pharmacologically active metabolite, SN-38. The proposed mechanism involves decreased exposure to SN-38, a topoisomerase I inhibitor linked to sacituzumab govitecan, which is metabolized via UGT1A1. Loss of antineoplastic efficacy may occur.', 'DDInter', 'Due to the potential loss of antitumour activity, concomitant use of sacituzumab govitecan with UGT1A1 inducers should be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46414/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46345, 'Bosentan', 'Saquinavir', 'Moderate', 'Coadministration of a protease inhibitor (PI) in combination with bosentan may increase the plasma concentration of bosentan and decrease that of the PI, unless ritonavir is included as a pharmacokinetic booster. Both PIs and bosentan are primarily metabolized by CYP450 3A4. Because PIs are also inhibitors of CYP450 3A4, they can inhibit the metabolic clearance of bosentan. Conversely, bosentan may induce the metabolism of PIs, although the effects are probably not significant in the presence of ritonavir, which is a potent CYP450 3A4 inhibitor.', 'DDInter', 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster. Dose adjustment of bosentan has been recommended. In patients who are starting bosentan and have been receiving PI therapy for at least 10 days, it has been recommended to start bosentan at 62.5 mg once daily or every other day based upon individual tolerability. When starting PI therapy in patients already on bosentan, it has been recommended to discontinue bosentan for at least 36 hours prior to initiation of PI therapy. After at least 10 days following the initiation of PI therapy, bosentan may be resumed at 62.5 mg once daily or every other day based upon individual tolerability. According to some authorities, use of the fixed combination atazanavir-cobicistat with bosentan is not recommended.', 'Metabolism', 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46415/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Probenecid, Tioconazole, More', 'Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46346, 'Bosentan', 'Saxagliptin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of saxagliptin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers. However, glycemic control should be closely monitored, and the physician notified if an interaction is suspected.', 'Metabolism', 'Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46416/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, More', 'Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Semaglutide, Dulaglutide, Exenatide, Miglitol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46347, 'Bosentan', 'Selpercatinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46417/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46348, 'Bosentan', 'Selumetinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.', 'DDInter', 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46418/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46349, 'Bosentan', 'Sibutramine', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46419/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More', 'Dexfenfluramine, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46350, 'Bosentan', 'Sildenafil', 'Moderate', 'Coadministration of bosentan and sildenafil may result in increased bosentan plasma concentrations and decreased sildenafil plasma concentrations. The mechanism is sildenafil inhibition of bosentan metabolism via CYP450 3A4 and 2C9, and bosentan induction of sildenafil metabolism via these same isoenzymes.', 'DDInter', 'No dosage adjustment of either drug is necessary, whether sildenafil is used for the treatment of pulmonary arterial hypertension (PAH) or erectile dysfunction. However, adding sildenafil to bosentan therapy does not provide any beneficial effect on exercise capacity in the treatment of PAH. If prescribed together, the possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should be considered. Patients should be advised to seek medical attention if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.', 'Metabolism', 'No dosage adjustment of either drug is necessary, whether sildenafil is used for the treatment of pulmonary arterial hypertension (PAH) or erectile dysfunction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46420/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 'Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46351, 'Bosentan', 'Silodosin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of silodosin, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46421/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Finasteride, Dutasteride, Alfuzosin, Terazosin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46352, 'Bosentan', 'Simvastatin', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of simvastatin and other HMG-CoA reductase inhibitors that are metabolized by the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of the isoenzyme by bosentan.', 'DDInter', 'The possibility of diminished HMG-CoA reductase inhibitory activity should be considered during concomitant use of atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) with bosentan. Cholesterol levels should be checked following initiation or discontinuation of bosentan therapy, and the dosage of HMG-CoA reductase inhibitor adjusted accordingly. Pravastatin and fluvastatin may be reasonable alternatives, since they are metabolized by other hepatic enzymes.', 'Metabolism', 'The possibility of diminished HMG-CoA reductase inhibitory activity should be considered during concomitant use of atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) with bosentan.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46422/', '', 'Ascorbic acid, Hydroflumethiazide, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Tioconazole, Furazolidone, Benzthiazide, Sulfamethizole, More', 'Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Semaglutide, Dulaglutide, Exenatide, Miglitol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46353, 'Bosentan', 'Siponimod', 'Major', 'Coadministration with drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 may decrease the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/strong CYP450 3A4 dual inducer or a moderate CYP450 2C9 inducer in combination with a separate strong CYP450 3A4 inducer.', 'DDInter', 'Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.g., carbamazepine, enzalutamide, rifampin) is not recommended for all patients. Concomitant use of siponimod and moderate or strong CYP450 3A4 inducers (e.g., apalutamide, bosentan, dabrafenib, dexamethasone, efavirenz, eslicarbazepine, etravirine, fosphenytoin, lorlatinib, lumacaftor, mitotane, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, St. John''s wort) is not recommended for patients with CYP450 2C9*1/*3 and *2/*3 genotypes.', 'Metabolism', 'Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46423/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46354, 'Bosentan', 'Sirolimus', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.', 'DDInter', 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46424/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Probenecid, Tioconazole, More', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46355, 'Bosentan', 'Nitrous acid', 'Moderate', 'Coadministration with antihypertensive agents, diuretics, vasodilators, or phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of sodium nitrite. Since sodium nitrite can cause serious hypotension and methemoglobin formation, patients may be at increased risk for complications related to inadequate perfusion and oxygenation.', 'DDInter', 'Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors. Hemodynamics should be monitored during and after administration of sodium nitrite, and the infusion rate decreased if significant hypotension occurs. In addition, methemoglobin levels should be monitored and oxygen administered during treatment whenever possible.', 'Synergism', 'Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46425/', '', 'Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Methionine, Deferiprone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46356, 'Bosentan', 'Solifenacin', 'Moderate', 'Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of solifenacin, which has been shown to be a substrate of the isoenzyme in vitro.', 'DDInter', 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46426/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Vardenafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46357, 'Bosentan', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46427/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46358, 'Bosentan', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46428/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46359, 'Bosentan', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46429/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46360, 'Bosentan', 'Sonidegib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46430/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46361, 'Bosentan', 'Sorafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which is partially metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46431/', '', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46362, 'Bosentan', 'Stiripentol', 'Moderate', 'Coadministration with inducers of CYP450 1A2, 2C19, and/or 3A4 may decrease the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.', 'DDInter', 'The potential for diminished pharmacologic effects of stiripentol should be considered during coadministration with CYP450 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of stiripentol should be considered during coadministration with CYP450 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46432/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Mephenytoin, Fenfluramine, Lamotrigine, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46363, 'Bosentan', 'Sunitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.', 'DDInter', 'The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or dose increase for sunitinib may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46433/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46364, 'Bosentan', 'Suvorexant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of suvorexant should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the suvorexant dosage adjusted as necessary.', 'Metabolism', 'The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46434/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46365, 'Bosentan', 'Tacrolimus', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.', 'DDInter', 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46435/', '', 'Ascorbic acid, Hydroflumethiazide, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Caffeine, Cromoglicic acid, Dupilumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46366, 'Bosentan', 'Tadalafil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', 'DDInter', 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.', 'Metabolism', 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46436/', '', 'Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Vardenafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46367, 'Bosentan', 'Tamoxifen', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46437/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, More', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46368, 'Bosentan', 'Tasimelteon', 'Moderate', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.', 'DDInter', 'The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46438/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46369, 'Bosentan', 'Tazemetostat', 'Major', 'Coadministration with moderate or potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible.', 'Metabolism', 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46439/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46370, 'Bosentan', 'Telaprevir', 'Moderate', 'Coadministration of bosentan with boceprevir or telaprevir is expected to increase the plasma concentrations of bosentan and decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitor. The proposed mechanism involves inhibition of bosentan metabolism via CYP450 3A4 and, conversely, induction of boceprevir and telaprevir metabolism via the same isoenzyme. The interaction has not been specifically studied with either boceprevir or telaprevir, but has been reported with HIV protease inhibitors.', 'DDInter', 'Caution is recommended if bosentan is used in combination with boceprevir or telaprevir. The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is also appropriate.', 'Metabolism', 'Caution is recommended if bosentan is used in combination with boceprevir or telaprevir.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46440/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, More', 'Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46371, 'Bosentan', 'Telithromycin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers. Pharmacologic response to telithromycin should be monitored closely during coadministration, and alternative treatment given if an interaction is suspected. Whenever possible, telithromycin should preferably not be used during or within 2 weeks after discontinuation of treatment with a CYP450 3A4 inducer.', 'Metabolism', 'The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46441/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, Darunavir, More', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46372, 'Bosentan', 'Telotristat ethyl', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', 'DDInter', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46442/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46373, 'Bosentan', 'Temsirolimus', 'Moderate', 'Coadministration of temsirolimus with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.', 'DDInter', 'In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided. When used for the treatment of renal cell carcinoma, some authorities advise a dose increase from the recommended 25 mg IV once weekly to 50 mg IV once weekly depending on patient tolerability. The dosage should be reduced to the normally recommended dose following discontinuation of the potent CYP450 3A4 inducer.', 'Metabolism', 'In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46443/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46374, 'Bosentan', 'Teniposide', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46444/', '', 'Topotecan', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46375, 'Bosentan', 'Terfenadine', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46445/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46376, 'Bosentan', 'Teriflunomide', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46446/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46377, 'Bosentan', 'Testosterone (topical)', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46447/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46378, 'Bosentan', 'Tioguanine', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', 'DDInter', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46448/', '', 'Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46379, 'Bosentan', 'Tiagabine', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46449/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Mephenytoin, Fenfluramine, Lamotrigine, Eslicarbazepine, Phensuximide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46380, 'Bosentan', 'Ticagrelor', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for diminished clinical response to ticagrelor therapy. Alternative treatment may be required if an interaction is suspected.', 'Metabolism', 'Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46450/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Betrixaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46381, 'Bosentan', 'Tipranavir', 'Moderate', 'Coadministration of a protease inhibitor (PI) in combination with bosentan may increase the plasma concentration of bosentan and decrease that of the PI, unless ritonavir is included as a pharmacokinetic booster. Both PIs and bosentan are primarily metabolized by CYP450 3A4. Because PIs are also inhibitors of CYP450 3A4, they can inhibit the metabolic clearance of bosentan. Conversely, bosentan may induce the metabolism of PIs, although the effects are probably not significant in the presence of ritonavir, which is a potent CYP450 3A4 inhibitor.', 'DDInter', 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster. Dose adjustment of bosentan has been recommended. In patients who are starting bosentan and have been receiving PI therapy for at least 10 days, it has been recommended to start bosentan at 62.5 mg once daily or every other day based upon individual tolerability. When starting PI therapy in patients already on bosentan, it has been recommended to discontinue bosentan for at least 36 hours prior to initiation of PI therapy. After at least 10 days following the initiation of PI therapy, bosentan may be resumed at 62.5 mg once daily or every other day based upon individual tolerability. According to some authorities, use of the fixed combination atazanavir-cobicistat with bosentan is not recommended.', 'Metabolism', 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46451/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46382, 'Bosentan', 'Tizanidine', 'Major', 'Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', 'DDInter', 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.', 'Synergism', 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46452/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, Tioconazole, More', 'Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Chlormezanone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46383, 'Bosentan', 'Tofacitinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of tofacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response; however, the extent to which these medications interact with tofacitinib has not been established.', 'DDInter', 'Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended when possible.', 'Metabolism', 'Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46453/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46384, 'Bosentan', 'Tolazamide', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46454/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More', 'Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Semaglutide, Dulaglutide, Exenatide, Miglitol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46385, 'Bosentan', 'Tolbutamide', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46455/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Amphotericin B, Clindamycin, Ciclopirox, Tioconazole, Brinzolamide, Clotrimazole, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46386, 'Bosentan', 'Tolterodine', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46456/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, More', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Vardenafil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46387, 'Bosentan', 'Tolvaptan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tolvaptan, which is primarily metabolized by the isoenzyme. When tolvaptan was administered with the potent CYP450 3A4 inducer rifampin, tolvaptan peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 85%.', 'DDInter', 'The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46457/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46388, 'Bosentan', 'Toremifene', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of toremifene. According to the product labeling, toremifene is primarily metabolized by CYP450 3A4 to N-demethyltoremifene, an antiestrogenic metabolite with weak in vivo antitumor potency but whose serum concentrations are 2 to 4 times higher than those of toremifene at steady state. The extent to which other, less potent CYP450 3A4 inducers may affect toremifene is unknown.', 'DDInter', 'The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of toremifene may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46458/', '', 'Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone', 'Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46389, 'Bosentan', 'Torasemide', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46459/', '', 'Etacrynic acid, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More', 'Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Darunavir, Ketoconazole, Tioconazole, Brinzolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46390, 'Bosentan', 'Trabectedin', 'Moderate', 'Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.', 'Synergism', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46460/', '', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Topotecan', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46391, 'Bosentan', 'Trazodone', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46461/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, Probenecid, Tioconazole, More', 'Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Escitalopram, Maprotiline, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46392, 'Bosentan', 'Tretinoin', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46462/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Probenecid, More', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46393, 'Bosentan', 'Triazolam', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46463/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Tioconazole, More', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46394, 'Bosentan', 'Troglitazone', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46464/', '', 'Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Semaglutide, Dulaglutide, Exenatide, Miglitol', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Trichlormethiazide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46395, 'Bosentan', 'Troleandomycin', 'Moderate', 'Coadministration of bosentan with a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 may result in increased plasma concentrations of bosentan and decreased plasma concentrations of the other drug. Bosentan itself is a substrate and inducer of both CYP450 2C9 and 3A4. Theoretically, bosentan may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.', 'DDInter', 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered. Clinical and/or laboratory monitoring may be appropriate whenever bosentan is added to or withdrawn from therapy, and the dosage of the concomitant drug adjusted as necessary. The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with combination CYP450 2C9/3A4 inhibitors (e.g., delavirdine, imatinib, miconazole, mifepristone, voriconazole) should probably be avoided also, if possible.', 'Metabolism', 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46465/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, More', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46396, 'Bosentan', 'Tucatinib', 'Moderate', 'Coadministration with CYP450 3A4 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by CYP450 2C8 and to a lesser extent by CYP450 3A4.', 'DDInter', 'The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46466/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, More', 'Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46397, 'Bosentan', 'Ubrogepant', 'Moderate', 'Coadministration with moderate or weak inducers of CYP450 3A4 may decrease the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme. Dedicated drug interaction studies have not been conducted to assess concomitant use of ubrogepant with moderate or weak CYP450 3A4 inducers.', 'DDInter', 'The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers. If needed, a second 100 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.', 'Metabolism', 'The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46467/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46398, 'Bosentan', 'Ulipristal', 'Moderate', 'The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme. Induction of CYP450 3A4 may last for up to 4 weeks after discontinuation of the enzyme inducer.', 'DDInter', 'Concomitant use of ulipristal with CYP450 3A4 inducers should be avoided if possible and nonhormonal emergency contraception should be considered.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46468/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Estetrol, Prasterone, Bazedoxifene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46399, 'Bosentan', 'Upadacitinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response.', 'DDInter', 'Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inducers. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46469/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (46400, 'Bosentan', 'Valdecoxib', 'Moderate', 'Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of those isoenzymes by bosentan.', 'DDInter', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever bosentan is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 2C9 and/or 3A4 are coadministered with bosentan, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/46470/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Vemurafenib, Probenecid, Tioconazole, More', 'Fenoprofen, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Esomeprazole, Tolmetin, Meclofenamic acid, Etodolac', 1767369485);
